RT Journal Article
SR Electronic
T1 The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.03.21256653
DO 10.1101/2021.06.03.21256653
A1 Ouellet, Véronique
A1 Erickson, Andrew
A1 Wiley, Kathy
A1 Morrissey, Colm
A1 Berge, Viktor
A1 Moreno, Carlos S.
A1 Tasken, Kristin Austlid
A1 Trudel, Dominique
A1 True, Lawrence D.
A1 Lewis, Michael S.
A1 Svindland, Aud
A1 Ertunc, Onur
A1 Vidal, Igor Damasceno
A1 Osunkoya, Adeboye O.
A1 Jones, Tracy
A1 Bova, G. Steven
A1 Lamminen, Tarja
A1 Achtman, Ariel H.
A1 Buzza, Mark
A1 Kouspou, Michelle M
A1 GAP1 UTMAs Contributing Investigators
A1 Bigler, Steven A
A1 Zhou, Xinchun
A1 Freedland, Stephen J.
A1 Mes-Masson, Anne-Marie
A1 Garraway, Isla P.
A1 Trock, Bruce J.
A1 Taimen, Pekka
A1 Saad, Fred
A1 Mirtti, Tuomas
A1 Knudsen, Beatrice S.
A1 De Marzo, Angelo M.
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.06.03.21256653.abstract
AB Background The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated TMAs from prostate cancer samples obtained from multiple institutions across several global locations.Methods Three separate TMA sets were built that differ by purpose and disease state.Results The intended use of TMA1 is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration resistant metastatic disease, and to compare molecular properties of high risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 was designed to address questions regarding risk of castration resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3’s intended use is to assess and better understand the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases.Conclusion The GAP1-UTMA project has succeeded in combining a large set of rare tissue specimens from 501 prostate cancer patients with rich clinical annotation.Impact This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe have developed a set of TMAs from a multi-institutional initiative supported by the Movember Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All centers received ethical review board permission to use patient material and conduct this study Comite d ethique de la recherche du CHUM (CE.14.128) the Institutional Review Board of the : JHU School of Medicine s the UMBMC the VA Greater Los Angeles (Department of Veterans Affairs PCC#2015-040408) the Ethics Committee of Hospital District of Helsinki and Uusimaa (84/13/03/00/2014; 3 30.01.2015) the Hospital District of Southwest Finland (number T206/2014) National Supervisory Authority for Welfare and Health for HUS and TYKS (VALVIRA 8008/06.01.03/2014) the Regional Committees for Medical and Health Research Ethics for OUH (REC 2013/1713) and Center for Healthcare Ethics for Cedar Sinai (Pro00033387 and Pro00020577). Patient informed consents were obtained as required by individual institutional ethical review boards (CHUM CE12.216 HUS TYKS and University of Washington Cedar Sinai) or waivers were granted (JHU OUH both VA Health Care System and UMBMC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe process to access the UTMA resource is outlined in Supplemental Figure 1. As part of a collaboration, the biomarker proposal form will be located on the Prostate Cancer Biorepository Network (PCBN) (25) website (www.prostatebiorepository.org).